Diabetic nephropathy

Diabetes Care

Volumn 31, Issue 4, 2008, Pages 823-827

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METFORMIN; METOPROLOL; PIOGLITAZONE; PLACEBO; RAMIPRIL; RESVERATROL; SULODEXIDE; TELMISARTAN; TRANDOLAPRIL;

ALBUMINURIA; ANEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY HYPERTROPHY; MICROALBUMINURIA; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PROTEINURIA; REVIEW; RISK FACTOR; URINARY EXCRETION; ARTICLE; CHRONIC KIDNEY FAILURE;

DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PROTEINURIA;

EID: 48649096419     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-zb04     Document Type: Review

References (24)

1. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. NEngl J Med 339:69-75, 1998
2. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E: Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2007 Dec 5 [epub ahead of print].
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296 -305, 2004
4. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48:1856-1862, 1999
5. Sowers JR: Hypertension, angiotensin II, and oxidative stress. N Engl J Med 346: 1999-2001, 2002
6. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781-2786, 2002
7. de Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D: Uremia causes endothelial progenitor cell deficiency. Kidney Int 66:641-646, 2004
8. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl JMed 348:593-600, 2003
9. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D: Stimulationof endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45:526-529, 2005
10. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney lnt 59:260-269, 2001
11. Afzali B, Haydar AA, Vinen K, Goldsmith DJ: From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 15: 2161-2168, 2004
12. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D: Erythro- poietin regulates endothelial progenitor cells. Blood 103:921-926, 2004
13. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12, 2003
14. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
15. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA: "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48:851-859, 1995
16. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treat- mentofangiotensin-II receptorblockerand angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117-124, 2003
17. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, MiddletonJ, Rostand SG, Miller E, Smith W, Bakris GL: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165:947-953, 2005
18. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Re- muzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEngl J Med 345:861-869, 2001
19. de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Re- muzzi G, Brenner BM, Shahinfar S: Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney Int 69:1675-1682, 2006
20. Heilig CW, Brosius FC 3rd, Cunningham C: Role for GLUT1 in diabetic glomerulo- sclerosis. Expert Rev Mol Med 8:1-18, 2006
21. Gnudi L, Viberti G, Raij L, Rodriguez V, Burt D, Cortes P, Hartley B, Thomas S, Maestrini S, Gruden G: GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury? Hypertension 42:19-24, 2003
22. Ricci C, Iacobini C, Oddi G, Amadio L, Menini S, Rastaldi MP, Frasheri A, PricciF, Pugliese F, Pugliese G: Role of TGF- beta/GLUT1 axis in susceptibility vs resistance to diabetic glomerulopathy in the Milan rat model. Nephrol Dial Transplant 21:1514-1524, 2006
23. Zintzaras E, Stefanidis I: Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet 50:84-91, 2005
24. Hodgkinson AD, Page T, Millward BA, Demaine AG: A novel polymorphism in the 5′ flanking region of the glucose transporter (GLUT1) gene is strongly associated with diabetic nephropathy in patients with type 1 diabetes mellitus. J Diabetes Compl 19:65-69, 2005